Tag : INTERMEDIATE-STAGE HCC

CONFERENCE UPDATE

Is combining locoregional and systemic therapy the new paradigm in intermediate HCC?
The debate highlighted the evolving role of combining locoregional and systemic therapy in intermediate-stage hepatocellular carcinoma (HCC), with potential to improve tumor response and facilitate conversion to curative treatment. However, concerns remain regarding toxicity, preservation of liver function, quality of life, and uncertain survival benefits, underscoring the importance of patient selection and individualized treatment.